Analyst Price Target is $10.88
▲ +245.24% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $10.88, with a high forecast of $21.00 and a low forecast of $6.00. The average price target represents a 245.24% upside from the last price of $3.15.
Current Consensus is
Hold
The current consensus among 8 polled investment analysts is to hold stock in Fulcrum Therapeutics. This Hold consensus rating has held steady for over two years.
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Read More